Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chemotherapy's hidden heart toll: study probes lasting damage in breast cancer survivors

NCT ID NCT07680855

Knowledge-focused Sponsor: University of Chile Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This observational study looks at how anthracycline chemotherapy affects inflammation, oxidative stress, and heart function in adult women who had breast cancer. Researchers measure blood markers and use echocardiograms to assess heart changes about 10 years after treatment. The goal is to understand long-term heart risks in survivors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
anthracycline chemotherapy
What this could lead to
If successful, this study could help identify early markers of heart damage in breast cancer survivors, potentially guiding future monitoring and prevention strategies.
What could go wrong
This is a small observational study with only 17 participants and no comparison group, so findings may not apply broadly. It aims to observe long-term effects, not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

17 people

The number who actually took part.

Started

Feb 2011

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult women with breast cancer treated at Hospital del Salvador, Santiago, Chile. Patients were consecutively recruited between 2010 and 2013 from a prospective cohort of individuals initiating anthracycline-based chemotherapy. A protocol amendment approved by the local ethics committee allowed long-term follow-up of the original cohort at 10 years for cardiovascular, inflammatory, and oxidative stress assessment.

Ages

18 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients with histologically confirmed breast cancer * Age between 18 and 75 years * Indication for anthracycline-based chemotherapy (\>200 mg/m²) * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Written informed consent signed prior to study participation * Availability for baseline cardiovascular and biomarker assessment and long-term follow-up Exclusion Criteria: * History of heart failure or left ventricular dysfunction (LVEF \<53%) * Known coronary artery disease or clinically significant ischemic heart disease * History of clinically significant arrhythmias or requirement for antiarrhythmic therapy * Dilated or hypertrophic cardiomyopathy * Moderate to severe valvular heart disease (mitral or aortic stenosis or regurgitation) * Congenital heart disease (including atrial or ventricular septal defects, patent ductus arteriosus, Ebstein anomaly, tetralogy of Fallot, coarctation of the aorta) * Chronic kidney disease (creatinine \>2 mg/dL) * Hepatic failure (bilirubin \>3 mg/dL, albumin \<3.5 g/dL, or prothrombin activity \<60% in absence of anticoagulation)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anthracycline related cardiotoxicity in breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cardiomyopathy due to anthracyclines Cardiotoxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anthracycline related cardiotoxicity in breast cancer Breast cancer Cardiotoxicity

More trials for these conditions

Other studies related to the condition(s) this trial covers.